TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01363583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoprostenol versus normal saline
Description: 0.5 ng/kilogram/minute during 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: epoprostenol versus normal saline
Description: 0.5 ng/kilogram/minute during 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.5-1.5 ml/hour during 4 days
Study: NCT01529736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High torque insertion
Description: Osseotite implant placed with high insertion torque forces

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low torque insertion
Description: Osseotite implant placed with low insertion torque forces
Study: NCT03101007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE Knee Prosthesis by DePuy
Description: Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE Knee Prosthesis by DePuy
Description: Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LCS Knee Prosthesis by DePuy
Description: Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCS Knee Prosthesis by DePuy
Description: Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
Study: NCT00413374

Intervention type: DRUG
Group type: OTHER
Intervention: Enoxaparin
Description: Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
Study: NCT03443232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation
Description: Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
Study: NCT03426631

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule 30 minutes before sleep

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAW1033B2 oral capsule
Description: DAW1033B2 capsule 30 minutes before sleep
Study: NCT00552448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Chest Compression VEST
Description: every 6 hours for 20 minutes
Study: NCT01313819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
Description: IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
Description: IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
Study: NCT04117763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Empagliflozin once daily, for three months
Study: NCT03851419

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of (Neuro)cysticercosis
Description: * Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of (Neuro)cysticercosis
Description: * Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium
Study: NCT04403594

Intervention type: OTHER
Intervention: dry needling
Description: dry needling followed by functional electrical stimulation and treadmill training
Study: NCT01694719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment for Depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Activation Treatment for Depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Study: NCT02578433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self Compassion
Description: Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
Study: NCT01771614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperglycemia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Study: NCT01965899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertable Cardiac Monitor Implant
Description: The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
Study: NCT03364413

Intervention type: OTHER
Intervention: Chocolate
Description: Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
Study: NCT00721175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biliary stent (self expandable metallic stent)
Description: metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS
Description: plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
Study: NCT01741337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation post-operative treatment for 6 months
Study: NCT03691779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablet orally once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablet orally once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA tablet orally once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA tablet orally once daily in the evening.
Study: NCT02303821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study: NCT02295033

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost irradiation
Study: NCT03099447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular electroacupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
Study: NCT03879382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/BCMA CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study: NCT03314155

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cerebral neuroinflammation evaluation
Description: Pet scan following an injection of the radiotracer (\[18F\]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
Study: NCT04052594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study: NCT03402308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Schisandra chinensis extract
Description: Schisandra chinensis extract 1,000 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch placebo 1,000 mg/day for 12 weeks
Study: NCT05556213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic examination
Description: laparoscopic examination for staging of endometriosis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sample to detect endometriosis
Study: NCT02303821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
Study: NCT03048591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
Study: NCT00858663

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy
Description: All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus) + Cisplatin
Description: All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan.
Study: NCT02138240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network intervention
Description: The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
Study: NCT00475215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium bromide solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium bromide solution for injection.
Study: NCT02315508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00063
Description: 800 mg orally, once a day, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, once a day, for 4 weeks
Study: NCT00496132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO131921
Description: Escalating doses by IV infusion
Study: NCT01561963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin Oral Capsules
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin IV Solution
Description: Intravenous (IV) solution
Study: NCT00048750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT03802539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass Liner
Description: restoration of root caries according to two different protocols
Study: NCT04361890

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: perineal ultrasound
Description: all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
Study: NCT01965223

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-fraction SABR
Description: Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Fraction SABR
Description: Single fraction SABR; 28Gy delivered in 1 fraction
Study: NCT02598128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RELiZORB
Description: Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham device
Study: NCT02794389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01930552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept AVE0005
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Pharmaceutical form:Solution for infusion Route of administration: Intravenous
Study: NCT01018095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 2 gm single dose versus 7 day 500 mg BID dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 2 gm single dose versus 7 day 500 mg BID dose
Study: NCT00617955

Intervention type: DRUG
Intervention: Aprotinin
Description: compare outcomes of Aprotinin versus Amicar

Intervention type: DRUG
Intervention: Amicar
Description: compare outcomes of Aprotinin versus Amicar
Study: NCT04018313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P39
Description: 150 mg/mL, Solution for injection in PFS

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Xolair
Description: 150 mg/mL, Solution for injection in PFS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P39
Description: 150 mg/mL, Solution for injection in PFS

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Xolair
Description: 150 mg/mL, Solution for injection in PFS

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Xolair
Description: 150 mg/mL, Solution for injection in PFS
Study: NCT04187742

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Comparison Email vs. Standard Email
Description: Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance Certification Email vs. Standard Email
Description: Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)
Description: Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
Study: NCT02220114

Intervention type: DRUG
Group type: OTHER
Intervention: Vigabatrin: Vigabatrin new ST formulation then Sabril®
Description: * first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~* second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision).
Study: NCT03994315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B. infantis EVC001
Description: Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)
Study: NCT03192384

Intervention type: BEHAVIORAL
Intervention: Educational programme
Description: Educational programme for ward staff
Study: NCT03620500

Intervention type: BEHAVIORAL
Intervention: Gross motor and developmental balance testing
Description: Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).